Delivery Order SPE2DB20D3101-SPE2DB25FRWC7
- Not listed
- The Defense Logistics Agency (DLA) awarded a $10,910.10 delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine in 0.5 mL syringes. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 24, 2025, performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order was competitively awarded and represents a single transaction under AmerisourceBergen's broader pharmaceutical supply framework with the federal government. This...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $71,577.02 to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in 0.5mL syringes, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a child delivery order under AmerisourceBergen's broader pharmaceutical supply agreement with the DLA. The place of performance is listed as Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,435.48 to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in syringe format (0.5mL). This non-set-aside contract, awarded on August 27, 2025, with an ultimate completion date of August 28, 2025, represents a firm fixed-price delivery order. The place of performance is listed as Conshohocken, Pennsylvania, which serves as AmerisourceBergen's corporate headquarters and a key distribution hub for the...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,109.28 to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine in syringe form (0.5mL). The contract, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a firm fixed price delivery order with no set-aside designation. Performance will occur at the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $7,836.90 to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine in 0.5mL syringe format. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of September 10, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical. The work will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine syringes (0.5ML) valued at $1,044.92 under a firm fixed price contract with an ultimate completion date of August 28, 2025. This non-set-aside award represents a single delivery order positioned as a child contract, leveraging the company's extensive pharmaceutical supply capabilities and established federal procurement relationships. The vaccine delivery will be performed at...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Boostrix TDAP vaccine in syringe form (0.5mL) with a ceiling value of $1,064.40. This competitively awarded, firm fixed-price delivery order was issued on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract utilizes no set-aside designation and will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is executed under...
- The Defense Logistics Agency awarded a $75,338.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in 0.5mL syringe format, with an ultimate completion date of August 18, 2025. This non-set-aside, competitively awarded contract represents a single delivery order fulfillment under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The vaccine will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,682.42 to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in 0.5mL syringes. This firm fixed-price, non-competitive delivery order was awarded on September 15, 2025, with an ultimate completion date of September 16, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider,...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Boostrix TDAP vaccine in 0.5 mL syringes, with a contract value of $9,228.10. This firm fixed-price delivery order, issued on August 25, 2025, represents a non-competitive award under the company's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million and extending through December 2026. The place of performance is AmerisourceBergen's...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRWC7Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for $9,404.28 to supply Boostrix TDAP vaccine in 0.5mL syringe format, with an ultimate completion date of September 23, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger pharmaceutical supply agreements with DLA. The vaccine will be performed at the contractor's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. As a major pharmaceutical distributor and critical federal medical vendor, AmerisourceBergen maintains an extensive portfolio of pharmaceutical and vaccine products supporting Defense Health Agency, military healthcare systems, and other federal customers globally. The company's federal contracting demonstrates consistent capability in delivering brand-name medications, generic drugs, vaccines, and medical supplies through competitive procurement mechanisms across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $9.4k | 9/22/25 |